Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt

Medizinische Hochschule Hannover

Gsf-Forschungszentrum Fur Umwelt Und Gesundheit, Gmbh

Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt Gmbh

Ludwig-Maximilians-Universitat München

Eximmium Biotechnologies Gmbh

Reinhard Zeidler

Wolfgang Hammerschmidt

Horst Lindhofer

Regina Feederle

Dagmar Pich

Hans-Joachim Kolb

Georg Bornkamm

Claudiu Supuran

Elisabeth Kremmer

Renata Stripecke

Bettina Von Neubeck

Stefanie Hauck

Gilbert Reisbach

Michaela Bauer

Constanze Slabik

Kerstin Stemmer

Christina Battke

Andrew Flatley

Matthias Tschöp

Romana Ruiss

Matthias TSCHÖP

The present invention provides herpesviruses, such as EBV, which lack at least one viral miRNA. Such herpesviruses lacking at least one viral miRNA are advantageously not capable of packaging their genome into the capsid, thereby producing HVLPs, which are substantially free of their herpesvirus genome or the nucleic acid molecule encoding the proteinaceous part of the HVLP and viral miRNA. Such HVLPs may be used as vaccine.

Means and methods for treating herpesvirus infection

An isolated chimeric antigen receptor (CAR) polypeptide, wherein the CAR includes an extracellular antigen-binding domain, including an antibody or antibody fragment that binds to a protein encoded by a herpes virus, or to a protein complex including the protein (herpes virus antigen), wherein the herpes virus antigen is present on the surface of a human cell that is latently infected with said herpes virus and supports the lytic phase of viral replication. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of the cell in the treatment of a medical disorder associated with human herpesvirus, such as herpes virus-associated cancers, chronic active herpes virus infections or primary herpes virus infections. In preferred embodiments the herpes virus is Epstein-Barr virus (EBV) and a preferred herpes virus antigen target of the CAR is the EBV glycoprotein 350/220 (gp350/gp220).

Chimeric antigen receptor and CAR-T cells that bind a herpes virus antigen

The present invention relates to improved anti-CD73 antibodies which, in comparison to prior art anti-CD73 antibodies bind to a membrane-bound form of CD73 protein having cancer-promoting role and inhibit its enzymatic activity, while essentially not inhibiting a soluble form of CD73 protein involved in cardioprotection. The present invention further relates to methods of generation of such specific anti-CD73 antibodies and uses thereof including uses as medicaments and in methods for treatment, amelioration, prophylaxis and diagnostics of cancer.

Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing

In general, the present invention relates to the field of (bio-)medicine and in particular to various metabolic diseases. Specifically, the invention provides means and methods for diagnosing, monitoring and predicting the risk for developing metabolic diseases. The invention uses exosomes as biomarkers for the aforementioned purposes. Moreover, an antibody of the present invention capable of specifically recognizing tissue-specific exosomes is also provided.

Tissue-specific exosomes as biomarkers

The present invention relates to a vaccine comprising a particle, said particle comprising (i) at least one Epstein-Barr virus (EBV) structural polypeptide, (ii) at least one EBV lytic polypeptide, (iii) membrane lipids, said particle being devoid of EBV DNA, wherein (a) the B-cell transformation capacity of one or more EBV polypeptides required for B-cell transformation as comprised in said particle is disabled while their immunogenicity is maintained; and or (b) said particle is devoid of one or more EBV polypeptides required for B-cell transformation. Furthermore, the invention relates to a method for generating a particle, to a cell obtained in the method of the invention, a kit comprising the vaccine or the particle generated according in the method of the invention. Also, the invention relates to the use of the vaccine or the particle generated according to the method of the invention for generating CD8+ cells specific for an EBV antigen.

Epstein-Barr-virus vaccine

The present invention relates to an antibody binding to a carbonic anhydrase, wherein the antibody comprises (a) the amino acid sequences SEQ ID NOS. 1 (CDR 1), 2 (CDR 2) and 3 (CDR 3) determining the CDRs of the Vregion, and the amino acid sequences SEQ ID NOS. 4 (CDR 1), 5 (CDR 2) and 6 (CDR 3) determining the CDRs of the Vregion; or (b) the amino acids sequences of (a), wherein at least one amino acid is conservatively substituted in any one of the amino acid sequences SEQ ID NOS. 1 to 6.

Antibody to a carbonic anhydrase

According to the invention there is described a method for ex vivo immunization of humans and animals comprising the following steps of:

Method for ex vivo immunization using heterologous intact bispecific and/or trispecific antibodies

According to the invention there is described a method for ex vivo immunization of humans and animals comprising the following steps:

Growing community of inventors

Olching, Germany

Reinhard Zeidler